Skip to content

Study · Animal study (in vivo) · rat · 2010

4 results

[Effect of the novel nootropic and neuroprotective dipeptide noopept on the streptozotocin-induced model of sporadic Alzheimer disease in rats].

Ostrovskaia RU, Tsaplina AP, Vakhitova IuV, Salimgareeva MKh, Iamidanov RS

Eksperimental'naia i klinicheskaia farmakologiia1 Jan 2010Cited by 3 (Europe PMC)

PMID20184279 (opens in a new tab)PepBankPUB-20184279
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In streptozotocin-treated rats, Noopept attenuated the reduction in NGF expression.

    In plain wordsIn rats treated with streptozotocin, Noopept reduced the loss of NGF expression.

    Peptide
    Noopept (omberacetam)
    Outcome
    IncreaseNGF expression
    Study

    ratsn: not reported in source

    Intracerebroventricular streptozotocin model of sporadic Alzheimer disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The new original cognition enhancing and neuroprotective dipeptide noopept decreases the aforementioned metabolic changes and the accompanying long-term deterioration of the memory.
    2 context sentences
    Summary · context
    Diabetogenic toxin streptozotocin (STZ) administered in both cerebral ventricles in a dose of 3 mg/kg decreases the expression of NGF and BDNF mainly in the hippocampus
    Summary · context
    Streptozotocin-intracerebroventricularly treated rats are proposed as an experimental model of sporadic Alzheimer disease (AD).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In streptozotocin-treated rats, Noopept attenuated the reduction in BDNF expression.

    In plain wordsIn rats treated with streptozotocin, Noopept reduced the loss of BDNF expression.

    Peptide
    Noopept (omberacetam)
    Outcome
    IncreaseBDNF expression
    Study

    ratsn: not reported in source

    Intracerebroventricular streptozotocin model of sporadic Alzheimer disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The new original cognition enhancing and neuroprotective dipeptide noopept decreases the aforementioned metabolic changes and the accompanying long-term deterioration of the memory.
    2 context sentences
    Summary · context
    Diabetogenic toxin streptozotocin (STZ) administered in both cerebral ventricles in a dose of 3 mg/kg decreases the expression of NGF and BDNF mainly in the hippocampus
    Summary · context
    Streptozotocin-intracerebroventricularly treated rats are proposed as an experimental model of sporadic Alzheimer disease (AD).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In streptozotocin-treated rats, Noopept attenuated the increase in brain malonic dialdehyde content.

    In plain wordsIn rats treated with streptozotocin, Noopept reduced the rise in a marker of fat oxidation in brain tissue.

    Peptide
    Noopept (omberacetam)
    Outcome
    DecreaseMalonic dialdehyde content
    Study

    ratsn: not reported in source

    Intracerebroventricular streptozotocin model of sporadic Alzheimer disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The new original cognition enhancing and neuroprotective dipeptide noopept decreases the aforementioned metabolic changes and the accompanying long-term deterioration of the memory.
    2 context sentences
    Summary · context
    and increases the content of malonic dialdehyde (MDA)--a product of lipid peroxidation--in the brain tissues.
    Summary · context
    Streptozotocin-intracerebroventricularly treated rats are proposed as an experimental model of sporadic Alzheimer disease (AD).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In streptozotocin-treated rats, Noopept reduced long-term memory deterioration.

    In plain wordsIn rats treated with streptozotocin, Noopept reduced long-term memory loss.

    Peptide
    Noopept (omberacetam)
    Outcome
    DecreaseLong-term memory deterioration
    Study

    ratsn: not reported in source

    Intracerebroventricular streptozotocin model of sporadic Alzheimer disease
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The new original cognition enhancing and neuroprotective dipeptide noopept decreases the aforementioned metabolic changes and the accompanying long-term deterioration of the memory.
    2 context sentences
    Summary · context
    These metabolic changes are accompanied by a pronounced cognitive deficiency, which is manifested by long-term memory deterioration in the passive avoidance test.
    Summary · context
    Streptozotocin-intracerebroventricularly treated rats are proposed as an experimental model of sporadic Alzheimer disease (AD).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.